Top

Published in:

01-12-2017 | Review

Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis

Authors: T. Saito, J. M. Sterbenz, S. Malay, L. Zhong, M. P. MacEachern, K. C. Chung

Published in: Osteoporosis International | Issue 12/2017

Abstract

Patients with osteoporotic fractures have an increased risk for secondary fractures. However, a rigorous study that assesses the effectiveness of individual osteoporotic drugs in preventing subsequent fractures is lacking. The purpose of this review was to analyze the effectiveness of anti-osteoporotic drugs in preventing secondary fractures. We searched for randomized controlled trials that showed the incidence of secondary fractures while using anti-osteoporotic drugs (bisphosphonates, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin) in MEDLINE, Embase.com, and Cochrane Central Register databases. We estimated risk ratios (RR) and numbers needed to treat (NNT) to prevent secondary fractures. Twenty-six studies met our eligibility criteria. There was a significant reduction in RR (0.38–0.77) after the use of anti-osteoporotic drugs for secondary vertebral fractures. Bisphosphonates and PTH significantly reduced the risk of a secondary non-vertebral fracture (RR 0.59 and 0.64). PTH needed the fewest number of patients to be treated to prevent a secondary vertebral fracture (NNT: 56). Our study demonstrated the effectiveness of anti-osteoporotic agents included in our systematic review in preventing secondary vertebral fractures. Bisphosphonates and PTH were most effective in preventing non-vertebral fractures. We suggest that clinicians should prescribe these drugs to prevent secondary vertebral/non-vertebral fractures.

Available only for authorised users

(US) OotSG (2004) In: bone health and osteoporosis: a report of the surgeon general. Reports of the Surgeon General, Rockville

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. doi:10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentral

Nih Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795

Deal CL (1997) Osteoporosis: prevention, diagnosis, and management. Am J Med 102(1A):35S–39SCrossRefPubMed

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11(7):556–561. doi:10.1007/s001980070075 CrossRefPubMed

Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297(4):387–394. doi:10.1001/jama.297.4.387 CrossRefPubMed

Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15(3):175–179. doi:10.1007/s00198-003-1514-0 CrossRefPubMed

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.1056/NEJMoa074941 CrossRefPubMed

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res Off J Am Soc Bone Miner Res 22(3):465–475. doi:10.1359/jbmr.061113 CrossRef

10.

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology G, The Osteoporosis Research Advisory G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570–578CrossRefPubMed

11.

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045. doi:10.4065/83.9.1032 CrossRefPubMedPubMedCentral

12.

Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437–1443CrossRefPubMed

13.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082CrossRefPubMed

14.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822CrossRefPubMed

15.

Sontag A, Wan X, Krege JH (2010) Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin 26(1):71–76. doi:10.1185/03007990903427082 CrossRefPubMed

16.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. [Erratum appears in N Engl J Med 2009 Nov 5;361(19):1914]. N Engl J Med 361(8):756–765. doi:10.1056/NEJMoa0809493 CrossRefPubMed

17.

Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350(9077):550–555. doi:10.1016/S0140-6736(97)02342-8 CrossRefPubMed

18.

Fleurence RL, Iglesias CP, Johnson JM (2007) The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. PharmacoEconomics 25(11):913–933CrossRefPubMed

19.

Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96(7):e52. doi:10.2106/JBJS.L.01781 CrossRefPubMed

20.

Kanis JA, Barton IP, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16(5):475–482CrossRefPubMed

21.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535–1541CrossRefPubMed

22.

Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K (1997) The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int 7(1):52–58CrossRefPubMed

23.

Palacios S, Kalouche-Khalil L, Rizzoli R, Zapalowski C, Resch H, Adachi JD, Gallagher JC, Feldman RG, Kendler DL, Wang A, Wagman RB, Adami S (2015) Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric 18(6):805–812. doi:10.3109/13697137.2015.1045484 CrossRefPubMed

24.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. doi:10.1016/j.jclinepi.2009.06.005 CrossRefPubMed

25.

Higgins JPT, Green S, Cochrane Collaboration (2008) Cochrane handbook for systematic reviews of interventions. Cochrane book series. Wiley-Blackwell, ChichesterCrossRef

26.

Pacifici R, McMurtry C, Vered I, Rupich R, Avioli LV (1988) Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab 66(4):747–753. doi:10.1210/jcem-66-4-747 CrossRefPubMed

27.

Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322(18):1265–1271CrossRefPubMed

28.

Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ et al (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323(2):73–79CrossRefPubMed

29.

Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH 3rd (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95(6):557–567CrossRefPubMed

30.

Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J (1994) Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79(6):1595–1599PubMed

31.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7(5):488–495CrossRefPubMed

32.

Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C (1997) The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol 16(4):354–360CrossRefPubMed

33.

Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104(3):219–226CrossRefPubMed

34.

Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109(4):267–276CrossRefPubMed

35.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91CrossRefPubMed

36.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340. doi:10.1056/NEJM200102013440503 CrossRefPubMed

37.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441. doi:10.1056/NEJM200105103441904 CrossRefPubMed

38.

Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17(6):1057–1064CrossRefPubMed

39.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(4):522–532CrossRefPubMed

40.

Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM, Fracture Intervention Trial Research G (2005) Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 80(3):343–349CrossRefPubMed

41.

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study G (2007) Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. [Summary for patients in Ann Intern Med. 2007 Mar 6;146(5):I20; PMID: 17339614]. Ann Intern Med 146(5):326–339CrossRefPubMed

42.

Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23(12):1923–1934. doi:10.1359/jbmr.080710 CrossRefPubMed

43.

Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22(3):983–991. doi:10.1007/s00198-010-1411-2 CrossRefPubMed

44.

Nakano T, Shiraki M, Sugimoto T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2014) Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab 32(4):441–446. doi:10.1007/s00774-013-0505-2 CrossRefPubMed

45.

Rozental TD, Makhni EC, Day CS, Bouxsein ML (2008) Improving evaluation and treatment for osteoporosis following distal radial fractures. A prospective randomized intervention. J Bone Joint Surg Am 90(5):953–961. doi:10.2106/JBJS.G.01121 CrossRefPubMed

46.

Hodsman AB, Hanley DA, Josse R (2002) Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ Can Med Assoc J 166(11):1426–1430

47.

Harvey NCW, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28(5):1507–1529. doi:10.1007/s00198-016-3894-y CrossRefPubMedPubMedCentral

48.

Hansen L, Mathiesen AS, Vestergaard P, Ehlers LH, Petersen KD (2013) A health economic analysis of osteoporotic fractures: who carries the burden? Arch Osteoporos 8(1-2):126. doi:10.1007/S11657-013-0126-3 CrossRefPubMedPubMedCentral

49.

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570–578. doi:10.1210/er.2001-9002 CrossRefPubMed

50.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Db Syst Rev 1:Cd004523. doi:10.1002/14651858.Cd004523.Pub3

51.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Db Syst Rev 1:Cd001155. doi:10.1002/14651858.Cd001155.Pub2

52.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Db Syst Rev 1:Cd003376. doi:10.1002/14651858.Cd003376.Pub3

53.

Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25(2):404–414. doi:10.1359/jbmr.090731 CrossRefPubMed

54.

Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93(17):1583–1587. doi:10.2106/JBJS.J.01379 CrossRefPubMed

55.

Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Aspenberg P, Caeiro JR, Marin F (2017) Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res 32(5):1040–1051. doi:10.1002/jbmr.3067 CrossRefPubMed

56.

Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97(19):1555–1562. doi:10.2106/JBJS.N.01275 CrossRefPubMed

57.

Inderjeeth CA, Chan K, Kwan K, Lai M (2012) Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab 30(5):493–503. doi:10.1007/s00774-012-0349-1 CrossRefPubMed

58.

Tosteson AN, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14(9):605–615PubMed

59.

Pfister AK, Welch CA, Lester MD, Emmett MK, Saville PD, Duerring SA (2006) Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 99(2):123–131. doi:10.1097/01.smj.0000202090.30647.61 CrossRefPubMed

60.

Parthan A, Deflin MM, Yurgin N, Huang J, Taylor DC (2012) Cost-effectiveness of denosumab versus oral bisphosphonates in the United States for post-menopausal osteoporosis (Pmo). Value Health 15(4):A38–A38CrossRef

61.

Mitchell PJ (2013) Best practices in secondary fracture prevention: fracture liaison services. Current 11(1):52–60. doi:10.1007/s11914-012-0130-3

62.

Gallacher SJ (2005) Setting up an osteoporosis fracture liaison service: background and potential outcomes. Best Pract Res Clin Rheumatol 19(6):1081–1094. doi:10.1016/j.berh.2005.07.001 CrossRefPubMed

63.

Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 27(3):873–879. doi:10.1007/s00198-015-3443-0 CrossRefPubMed

64.

Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JEM, Wahl DA, Grp ICFW (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22(7):2051–2065. doi:10.1007/s00198-011-1642-x CrossRefPubMed

65.

Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E, Fractur ATFS (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039–2046. doi:10.1002/jbmr.1698 CrossRefPubMed

66.

Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24(8):2135–2152. doi:10.1007/s00198-013-2348-z CrossRefPubMedPubMedCentral

67.

MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148(3):197–213CrossRefPubMed

68.

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967. doi:10.1056/NEJMoa074941 CrossRefPubMedCentral

Title: Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis
Authors: T. Saito
J. M. Sterbenz
S. Malay
L. Zhong
M. P. MacEachern
K. C. Chung
Publication date: 01-12-2017
Publisher: Springer London
Published in: Osteoporosis International / Issue 12/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4175-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2017

Validity, reliability, and responsiveness to change of the “Osteoporosis and You” knowledge scale

Reduced kidney function is associated with BMD, bone loss and markers of mineral homeostasis in older women: a 10-year longitudinal study

Is drug-induced bone loss acceptable in premenopausal women? A practical fracture risk modeling exercise

Equal treatment: no evidence of gender inequity in osteoporosis management in a coordinator-based fragility fracture screening program

Assessing impact of body mass index on risk of acute kidney injury and mortality in elderly patients undergoing hip fracture surgery

Gender-specific association between dietary acid load and total lean body mass and its dependency on protein intake in seniors